thalidomide has been researched along with Hypermelanosis in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Milrod, CJ | 1 |
| Blevins, F | 1 |
| Hughes, D | 1 |
| Lerner, A | 1 |
| Sarosiek, S | 1 |
| Sanchorawala, V | 1 |
| Sloan, JM | 1 |
| Di Cesare, A | 1 |
| Pescitelli, L | 1 |
| Ricceri, F | 1 |
| Lazzeri, L | 1 |
| Prignano, F | 1 |
| McCarthy, S | 1 |
| Heffron, CCBB | 1 |
| Murphy, M | 1 |
| Zhao, X | 1 |
| Shi, R | 1 |
| Jin, X | 1 |
| Zheng, J | 1 |
| Guarenti, I | 1 |
| Sebastiani, V | 1 |
| Pinto, G | 1 |
| de Souza, PR | 1 |
| de Almeida, H | 1 |
5 other studies available for thalidomide and Hypermelanosis
| Article | Year |
|---|---|
Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs.
Topics: Black or African American; Humans; Hyperpigmentation; Immunologic Factors; Incidence; Lenalidomide; | 2021 |
Cutaneous hyperpigmentation induced by apremilast.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Facial Dermatoses; Female; Foll | 2018 |
Lentigines within fixed drug eruption: reply to 'Multiple lentigines arising on resolving psoriatic plaques after treatment with apremilast'.
Topics: Adult; Dermoscopy; Drug Eruptions; Exanthema; Female; Humans; Hyperpigmentation; Inflammation; Lenti | 2019 |
Diffuse hyperpigmented plaques as cutaneous manifestation of multicentric Castleman disease and treatment with thalidomide: report of three cases.
Topics: Adult; Biopsy, Needle; Castleman Disease; Diagnosis, Differential; Drug Therapy, Combination; Female | 2011 |
Successful treatment of scleromyxedema with oral thalidomide.
Topics: Adult; Humans; Hyperpigmentation; Immunosuppressive Agents; Male; Paraproteinemias; Scleromyxedema; | 2013 |